Shinji Kitamura

Prof. Shinji Kitamura


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
Kenji TsujiKenji Tsuji
Kenji Tsuji
NUNaruhiko Uchida
Naruhiko Uchida
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SHSoichiro Haraguchi
Soichiro Haraguchi
JWJun Wada
Jun Wada
The gut–kidney axis represents the complex interactions between the gut microbiota and kidney, which significantly impact the progression of chronic kidney disease (CKD) and overall patient health. In CKD patients, imbalances in the gut microbiota promote the production of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, which impair renal function and contribute to systemic inflammation. Mechanisms like endotoxemia, immune activation and oxidative stress worsen renal damage by activating pro-inflammatory and oxidative pathways. Insights into these mechanisms highlight the impact of gut-derived metabolites, bacterial translocation, and immune response changes on kidney health, suggesting new potential approaches for CKD treatment. Clinical applications, such as dietary interventions, prebiotics, probiotics and fecal microbiota transplantation, are promising in adjusting the gut microbiota to alleviate CKD symptoms and slow disease progression. Current research highlights the clinical relevance of the gut–kidney axis, but further study is essential to clarify these mechanisms’ diagnostic biomarkers and optimize therapeutic interventions. This review emphasizes the importance of an integrated approach to CKD management, focusing on the gut microbiota as a therapeutic target to limit kidney injury.

18 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Kenji TsujiKenji Tsuji
Kenji Tsuji
NUNaruhiko Uchida
Naruhiko Uchida
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SHSoichiro Haraguchi
Soichiro Haraguchi
JWJun Wada
Jun Wada
The gut-kidney axis represents the complex interactions between the gut microbiota and renal function, which significantly impact the progression of chronic kidney disease (CKD) and overall patient health. On CKD patients, imbalances in the gut microbiota promote the production of uremic toxins like indoxyl sulfate and p-cresyl sulfate, which impair renal function and contribute to systemic inflammation. Mechanisms like endotoxemia, immune activation and oxidative stress worsen renal damage by activating pro-inflammatory and oxidative pathways. Insights into these mechanisms reveal the impact of gut-derived metabolites, bacterial translocation, and immune response changes on kidney health, suggesting new approaches for CKD treatment. Clinical applications like dietary interventions, prebiotics, probiotics and fecal microbiota transplantation show promise in adjusting the gut microbiota to alleviate CKD symptoms and slow disease progression. Current research highlights the clinical relevance of the gut-kidney axis, but further study is essential to clarify these mechanisms, diagnostic biomarkers, and optimize therapeutic interventions. This review emphasizes the importance of an integrated approach to CKD management, focusing on the gut microbiota as a therapeutic target to limit kidney injury.

9 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Kenji TsujiKenji Tsuji
Kenji Tsuji
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SKShinji Kitamura
Shinji Kitamura
JWJun Wada
Jun Wada
Acute kidney injury (AKI) is a clinical syndrome where a rapid decrease in kidney function and/or urine output is observed, which may result in the imbalance of water, electrolytes and acid base. It is associated with poor prognosis and prolonged hospitalization. Therefore, an early diagnosis and treatment to avoid the severe AKI stage are important. While several biomarkers, such as urinary L-FABP and NGAL, can be clinically useful, there is still no gold standard for the early detection of AKI and there are limited therapeutic options against AKI. miRNAs are non-coding and single-stranded RNAs that silence their target genes in the post-transcriptional process and are involved in a wide range of biological processes. Recent accumulated evidence has revealed that miRNAs may be potential biomarkers and therapeutic targets for AKI. In this review article, we summarize the current knowledge about miRNAs as promising biomarkers and potential therapeutic targets for AKI, as well as the challenges in their clinical use.

20 February 2025 in American Journal of Nephrology
Verified
Journal Article
Open access
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
Kenji TsujiKenji Tsuji
Kenji Tsuji
KFKazuhiko Fukushima
Kazuhiko Fukushima
SHSoichiro Haraguchi
Soichiro Haraguchi
SKShinji Kitamura
Shinji Kitamura
JWJun Wada
Jun Wada
Introduction: Acute kidney injury associated with the consumption of Beni-koji CholesteHelp supplements, which contain red yeast rice (Beni-Koji), has become a significant public health concern in Japan. While renal biopsy findings from several case reports have suggested tubular damage, no definitive causal relationship has been established, and the underlying mechanisms of kidney injury remain poorly understood. The complexity of identifying toxic substances in supplements containing various bioactive compounds makes conventional investigative approaches both time-consuming and challenging. This highlights an urgent need to establish a reliable platform for assessing organ-specific toxicity in such supplements. In this study, we utilized a kidney organoid model derived from adult rat kidney stem cells (KS cells) to assess the potential tubular toxicity of these supplements. Methods: KS cell clusters were cultured in three-dimensional system supplemented with growth factors to promote kidney organoids. The organoids were subsequently exposed to Beni-koji CholesteHelp supplements or cisplatin, followed by histological and molecular analyses to evaluate structural impacts. Results: Established organoids had the kidney-like structures including tubular-like structures and glomerulus-like structures at the tips of multiple tubules. Treatment with Beni-koji CholesteHelp supplements induced significant tubular damage in the organoids, characterized by epithelial cell thinning, structural disruption, and increase in cleaved-caspase 3-positive apoptotic tubular cells, similar to the organoids treated with cisplatin. Conclusion: These findings provide the first evidence suggesting that certain toxicants in specific batches of Beni-koji CholesteHelp supplements cause direct renal tubular injury. This KS cell-based organoid system represents a cost-effective, reproducible, and technically simple platform for nephrotoxicity screening.

25 September 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
YSYizhen Sang
Yizhen Sang
Kenji TsujiKenji Tsuji
Kenji Tsuji
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SKShinji Kitamura
Shinji Kitamura
JWJun Wada
Jun Wada
Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is a secreted and membrane-associated protein, which regulates diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence has revealed that excess SEMA3A expression and the subsequent signaling pathway aggravate kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports have demonstrated that the inhibition of SEMA3A ameliorated kidney injury via a reduction in cell apoptosis, fibrosis and inflammation; thus, SEMA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized the current knowledge regarding the role of SEMA3A in kidney pathophysiology and their potential use in kidney diseases.

31 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
YSYizhen Sang
Yizhen Sang
Kenji TsujiKenji Tsuji
Kenji Tsuji
HNHiroyuki Nakanoh
Hiroyuki Nakanoh
KFKazuhiko Fukushima
Kazuhiko Fukushima
SKShinji Kitamura
Shinji Kitamura
JWJun Wada
Jun Wada
Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is the secreted and membrane-associated proteins, which regulate diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence revealed that excess SEMA3A expression and subsequent signaling pathway aggravates kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports demonstrated that inhibition of SEMA3A ameliorated kidney injury via reduction of cell apoptosis, fibrosis and inflammation, thus SE-MA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized current knowledges regarding the role of SEMA3A signaling in kidney pathophysiology and their potential use in kidney diseases.